Posted in

Are there any new developments in veterinary API raw materials?

Hey there, fellow pet industry folks, vet clinic teams, and small-batch animal pharmaceutical peeps – if you’ve been deep in the weeds of sourcing veterinary API raw materials lately, you know how wild the last couple of years have been. I’ve been on this side of the table for 12 years now, running a small (but scrappy) veterinary API raw materials supply operation, and the questions I get most these days are: “Is the shortage stuff finally easing? And what’s actually new on the API development front that we haven’t heard of?” Let’s cut through the noise, skip the corporate jargon, and talk about the real, actionable stuff that’s not just hype. Veterinary API Raw Materials

First off, let’s circle back to the supply chain chaos that dominated 2021–2023, because that’s been the backdrop for every single new development in vet APIs, in my opinion. A lot of folks I talk to still think API shortages are permanent, but here’s the thing: we’re not out of the woods, but we’re not in the same swamp either. The big issue back then was that most generic vet APIs were made in a handful of facilities, mostly in Asia, and when COVID hit, those factories shut down, shipping got backed up, and suddenly every clinic was scrambling for things like metronidazole or amoxicillin raw materials.

Wait, but what’s new now? Oh right, two huge shifts. First, regulatory bodies (like the FDA’s Center for Veterinary Medicine, or CVM, and EMA’s VMD) finally started cracking down on that concentration risk. Not just making vague rules, but actually launching programs to get more vet API production online specifically for animals – not the human side, which was hoarding supplies. For example, CVM’s “Veterinary Generic API Manufacturing Initiative” that launched in 2023 has already approved three new small-scale US-based facilities dedicated solely to vet API production. Before that, if you wanted a vet-specific API facility in the States, you were looking at, like, one or two big players. Now we’ve got small batch-friendly plants, which is perfect for folks like us who work with smaller pharma companies or compounding pharmacies that don’t need 10,000-liter batches. That’s a game-changer because it cuts shipping times from 6 weeks to 5 days for domestic orders, and it means less risk of a total shutdown if one factory has a power outage or a regulatory blip.

Second, a lot of people don’t realize that most vet APIs are just repurposed human APIs, but there’s been a massive push for species-specific APIs lately. Like, think about it: dogs and cats metabolize drugs way differently than humans or even horses or cows. For example, a pain reliever that’s safe for humans will kill a cat if dosed wrong, even if it’s the same active ingredient. So now, researchers are developing APIs that are tailored to how specific animals process compounds. The biggest one I’ve seen traction on is a new form of feline-specific gabapentin – wait, no, not a generic that’s repackaged, a modified API that has a slower release rate, so cats don’t get that weird sedative crash that makes clinics have to monitor patients for hours post-pill. We started sourcing the first commercial batch of that API back in January, and we’ve already sent it to four compounding labs in the Midwest that report it’s cut their post-administration follow-up time by 70% for post-surgical cats. That’s not just a tiny tweak – that’s actual improvement in animal care.

Another big development in raw materials is green API production. Everyone’s been talking about sustainability in pharma, but for vet APIs, that’s been slow because so many manufacturers were focused on getting supplies out fast during the shortage. Now we’re seeing a bunch of new processes that cut waste by 40% or more. For example, a German-based API supplier we partner with (they’re not big enough to work with the huge pharma guys, so they focus on niche vet APIs) developed a way to make a common antibiotic for livestock (oxytetracycline, if you’re familiar) using 30% less water and 25% less energy than traditional methods. The cool part? This API is CVM-approved, so it’s not some untested lab experiment. We started carrying it last quarter, and a lot of our livestock and equine clients are switching over because they can use it without sacrificing batch size or quality, and it fits with their own farm sustainability goals.

But wait, let’s get real – it’s not all sunshine and roses. There’s a big gap between “new development” and “something we can actually get our hands on.” For example, there’s a lot of hype around mRNA-based vet APIs, right? For things like pet cancer treatments or even vaccines, but let’s be clear: mRNA APIs for vet use are still in early clinical trials, and we’re talking at least 5–7 years before they’re commercially available. Most of the “new stuff” that’s actually actionable right now is modified release APIs and supply chain diversification, not fancy tech that’s still in a lab. That’s important because a lot of suppliers will try to sell you on unproven stuff to charge more, so it pays to separate the clinical trial noise from the stuff you can order today.

Also, let’s talk about something that’s been a huge pain point for our clients: price stability. Back in 2022, we saw some vet API raw material prices jump 300% because of the shortage. Now? Prices are coming down, but not to pre-pandemic levels – and that’s because of these new regional facilities. Because now we’ve got more suppliers, we don’t have to mark up prices as much to cover shipping or the risk of waiting for a single batch from overseas. For example, the modified feline gabapentin I mentioned earlier is only 12% more expensive than generic gabapentin for humans, which is way lower than the 40% premium some people predicted for a species-specific API. That’s a win for clinics, because they don’t have to pass huge costs onto pet owners.

I should also mention the role of compounding pharmacies here, because they’re a huge part of the vet API market that gets overlooked. Compounding used to be kind of a gray area when it came to API quality, but the new developments in raw materials have pushed regulators to set stricter standards for compounding APIs. CVM updated their guidelines in 2024, so now APIs for compounding have to meet the same purity and testing standards as API for commercial drugs. That means we’ve had to step up our own testing – we now do three quality checks on every batch before we ship it, not just one – but it’s good because it’s leading to more consistent, safe products for animals.

Let’s get personal, too. I had a client last month who runs a small animal clinic in Ohio, and they were telling me that before the new domestic API facilities opened, they were rationing meloxicam (a common pain reliever) because their usual supplier was backordered for 8 weeks. Now, he orders from one of the new US-based facilities we work with, and he gets his batch in 3 days. That’s not just a supply chain win – that means more animals get pain relief when they need it, not when the shipment finally arrives. That’s the stuff that actually matters, not just industry buzzwords.

Another thing I’ve noticed is a big push for combination APIs that are tailored to specific animal conditions. Like, instead of a cat getting two separate pills for anxiety and urinary tract issues, there’s a new combination API that combines two low-dose drugs that don’t interact, made specifically for feline urinary tract dysfunction and stress. We tested this API in our lab (wait, no, we don’t do formulation testing, but we worked closely with the developer to verify the purity) and it’s been super popular with small animal clinics. It cuts down on admin time for vets and pet stress from giving multiple pills, which is a huge deal – anyone who’s ever tried to give a cat a pill knows that battle is real.

But let’s not ignore the challenges that still exist. A lot of the new API developments are for small-animal use, right? Dogs and cats, but what about livestock and large animals? We’re still waiting for a lot of species-specific APIs for cows, horses, and pigs, because the market for large-animal vet APIs is smaller, so manufacturers don’t see as much profit in developing them. That’s something the industry’s still pushing on, with groups like the Animal Health Institute lobbying for tax incentives for API development for large animals, because right now, the money is in small pets.

So, putting this all together: the biggest, most useful new developments in vet API raw materials right now aren’t some fancy new molecule that cures every disease. They’re practical, accessible stuff: domestic production that cuts lead times and reduces shortage risk, species-specific APIs that improve animal care, sustainable manufacturing processes that lower waste and costs, and stricter quality standards that make raw materials more reliable. A lot of the hype around “new vet APIs” is overblown, but the stuff that’s actually hitting the market is making a tangible difference for clinics, pet owners, and the animals we care for.

If you’re a vet clinic manager, a compounding pharmacy owner, a small animal pharma rep, or anyone who needs consistent, high-quality vet API raw materials, I’m here to help. We don’t carry every new fancy lab API (yet), but we stick to the stuff that’s tested, approved, and actually works for your daily operations. Shoot us a message whenever you want to chat about current stock, pricing, or how any of these new developments can fit into your supply chain.

Male Health Raw Materials References

  1. U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine. (2023). Veterinary Generic API Manufacturing Initiative: First Annual Progress Report.
  2. European Medicines Agency (EMA) Veterinary Medicines Agency (VMD). (2024). Species-Specific Veterinary API Development: Regulatory Update and Market Landscape.
  3. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). (2024). Sustainability in Veterinary API Manufacturing: Current Practices and Future Trends.
  4. Animal Health Institute (AHI). (2024). Large Animal Veterinary API Market Gap Analysis and Policy Recommendations.

Henan Jinyi Import & Export Co., Ltd.

Address: Block A, Building 3, No.7 Guoji Road, Jinshui District, Zhengzhou City, Henan Province
E-mail: 13838041990@163.com
WebSite: https://www.jyingredients.com/